<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973101</url>
  </required_header>
  <id_info>
    <org_study_id>NP 217/2012</org_study_id>
    <nct_id>NCT01973101</nct_id>
  </id_info>
  <brief_title>Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.</brief_title>
  <acronym>CIRCE</acronym>
  <official_title>Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de S達o Paulo</source>
  <brief_summary>
    <textblock>
      The purpose of this phase II study is to determine the survival free disease of patients
      diagnosed with invasive locally advanced carcinomas of uterine cervix treated with induction
      chemotherapy with cisplatin and gemcitabine followed by chemoradiation and definitive
      chemoradiation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From the randomization until the end of the treatment - up to 36 month.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>36 month after the end of the treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional disease control rate</measure>
    <time_frame>36 month after the end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic toxicity in both arms</measure>
    <time_frame>From the randomization until the end of the treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 month after the end of the treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t</condition>
  <arm_group>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin, radiotherapy and brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>50 mg/m2 - Day 1</description>
    <arm_group_label>Chemo-induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2 on day 1 and day 8.</description>
    <arm_group_label>Chemo-induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.</description>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45 Gy</description>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>80 Gy</description>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced carcinoma of uterine cervix histological confirmed.

          2. Indication for definitive chemoradiation treatment;

          3. Measurable disease by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
             criteria;

          4. Age between 18 years old and 70 years old;

          5. Adequate bone marrow and organ function defined by laboratory values;

          6. Non evidence of disease in para-aortic lymph node;

        Exclusion Criteria:

          1. Previous treatment with Chemotherapy or radiotherapy

          2. Previous surgery for primary tumor;

          3. Distant metastasis;

          4. Performance status according to Eastern Cooperative Oncology Group greater than 2;

          5. Peripheric neuropathy greater than grade 2 by National Cancer Institute Common
             Toxicity Criteria for Adverse Events (NCI-CTCAE) version 3.0;

          6. Significant Cardiac disease (history of and/or active disease);

          7. Other treatment for cancer, including hormonotherapy;

          8. Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Del Pilar Estevez Diz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de S達o Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Del Pilar Estevez Diz, MD</last_name>
    <phone>55 11 3893-2000</phone>
    <email>pesquisa.clinica@icesp.org.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICESP</name>
      <address>
        <city>S達o Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Del Pilar Estevez Diz, MD</last_name>
      <phone>55 11 3893-2000</phone>
      <email>pesquisa.clinica@icesp.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced carcinomas of uterine cervix</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Chemo-induction</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

